{
    "id": 18745,
    "fullName": "CLU positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "CLU positive indicates the presence of the CLU gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 1191,
        "geneSymbol": "CLU",
        "terms": [
            "CLU",
            "AAG4",
            "APO-J",
            "APOJ",
            "CLI",
            "CLU1",
            "CLU2",
            "KUB1",
            "NA1/NA2",
            "SGP-2",
            "SGP2",
            "SP-40",
            "TRPM-2",
            "TRPM2"
        ]
    },
    "variant": "positive",
    "createDate": "02/26/2016",
    "updateDate": "10/08/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 5046,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Custirsen (OGX-011) treatment resulted in dose-dependent decrease of clusterin expression in prostate tumors in patients (PMID: 16145049).",
            "molecularProfile": {
                "id": 19099,
                "profileName": "CLU positive"
            },
            "therapy": {
                "id": 3643,
                "therapyName": "Custirsen",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4857,
                    "pubMedId": 16145049,
                    "title": "A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/16145049"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4772,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Custirsen in combination with Taxotere (docetaxel) and Prednisone resulted in improved median progression-free survival and overall survival (7.3 and 23.8 months, respectively) compared to Taxotere (docetaxel) and Prednisone treatment (6.1 and 16.9 months, respectively) in patients with metastatic castration-resistant prostate cancer (PMID: 20733135).",
            "molecularProfile": {
                "id": 19099,
                "profileName": "CLU positive"
            },
            "therapy": {
                "id": 3646,
                "therapyName": "Custirsen + Docetaxel + Prednisone",
                "synonyms": null
            },
            "indication": {
                "id": 2526,
                "name": "prostate adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4724,
                    "pubMedId": 20733135,
                    "title": "Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20733135"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 4775,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/II clinical trial, the combination of Custirsen, Gemzar (gemcitabine), Platinol (cisplatin) or Paraplatin (carboplatin) resulted in overall response in 31% (25/81), 1-year survival in 54% (44/81), and 2-year survival in 30% (24/81) of patients with stage IIIB/IV non-small cell lung cancer (PMID: 22198426).",
            "molecularProfile": {
                "id": 19099,
                "profileName": "CLU positive"
            },
            "therapy": {
                "id": 3650,
                "therapyName": "Carboplatin + Custirsen + Gemcitabine",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4726,
                    "pubMedId": 22198426,
                    "title": "Phase I/II trial of custirsen (OGX-011), an inhibitor of clusterin, in combination with a gemcitabine and platinum regimen in patients with previously untreated advanced non-small cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22198426"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4774,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/II clinical trial, the combination of Custirsen, Gemzar (gemcitabine), and Platinol (cisplatin) or Paraplatin (carboplatin) resulted in overall response in 31% (25/81), 1-year survival in 54% (44/81), and 2-year survival in 30% (24/81) of patients with stage IIIB/IV non-small cell lung cancer (PMID: 22198426).",
            "molecularProfile": {
                "id": 19099,
                "profileName": "CLU positive"
            },
            "therapy": {
                "id": 3651,
                "therapyName": "Cisplatin + Custirsen + Gemcitabine",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4726,
                    "pubMedId": 22198426,
                    "title": "Phase I/II trial of custirsen (OGX-011), an inhibitor of clusterin, in combination with a gemcitabine and platinum regimen in patients with previously untreated advanced non-small cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22198426"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5047,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Custirsen (OGX-011) treatment decreased serum clusterin in patients with prostate, breaset and lung cancers, without affecting pharmacokinetics of Taxotere (docetaxel) (PMID: 18245546).",
            "molecularProfile": {
                "id": 19099,
                "profileName": "CLU positive"
            },
            "therapy": {
                "id": 3648,
                "therapyName": "Custirsen + Docetaxel",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4859,
                    "pubMedId": 18245546,
                    "title": "A phase I study of OGX-011, a 2'-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18245546"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4769,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Custirsen and Taxotere (docetaxel) combination treatment resulted in partial response in 33% (5/15) and stable disease in 60% (9/15) of breast cancer patients (PMID: 19147778).",
            "molecularProfile": {
                "id": 19099,
                "profileName": "CLU positive"
            },
            "therapy": {
                "id": 3648,
                "therapyName": "Custirsen + Docetaxel",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4720,
                    "pubMedId": 19147778,
                    "title": "Phase II trial of OGX-011 in combination with docetaxel in metastatic breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19147778"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 4773,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Custirsen treatment in combination with Mitoxantrone and Prednisone resulted in overall survival of 11.5 months and favorable pain response in patients with metastatic castration-resistant prostate adenocarcinoma (PMID: 21788353).",
            "molecularProfile": {
                "id": 19099,
                "profileName": "CLU positive"
            },
            "therapy": {
                "id": 3649,
                "therapyName": "Custirsen + Mitoxantrone + Prednisone",
                "synonyms": null
            },
            "indication": {
                "id": 2526,
                "name": "prostate adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4725,
                    "pubMedId": 21788353,
                    "title": "Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21788353"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        }
    ],
    "molecularProfiles": [
        {
            "id": 19099,
            "profileName": "CLU positive",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}